Recent advances in topical delivery of proteins and peptides mediated by soft matter nanocarriers

Biotechnology Advances

Volumn 33, Issue 6, 2015, Pages 1355-1369

  Witting, Madeleine ^a   Obst, Katja ^b   Friess, Wolfgang ^a   Hedtrich, Sarah ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Biopharmaceuticals; Dermal; Nasal; Ocular; Peptides; Proteins; Pulmonary; Soft matter nanocarrier; Targeted drug delivery; Topical delivery

Indexed keywords

BIOCOMPATIBILITY; DISEASES; DRUG DELIVERY; PEPTIDES;

BIOPHARMACEUTICALS; DERMAL; NANOCARRIERS; NASAL; OCULAR; PULMONARY; TARGETED DRUG DELIVERY; TOPICAL DELIVERY;

PROTEINS;

BIOTECHNOLOGY; CANCER; DISEASE TREATMENT; DRUG; NANOPARTICLE; PEPTIDE; PROTEIN; SKIN; TECHNOLOGICAL DEVELOPMENT;

CHITOSAN; DRUG CARRIER; EMULSION; LIPOSOME; NANOMATERIAL; NANOPARTICLE; PROTEIN;

ADMINISTRATION AND DOSAGE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; EMULSION; FUNCTIONS OF THE SKIN AND ITS APPENDAGES; HUMAN; LUNG; PROCEDURES; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; CHITOSAN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EMULSIONS; HUMANS; LIPOSOMES; LUNG; NANOPARTICLES; NANOSTRUCTURES; PROTEINS; SKIN PHYSIOLOGICAL PHENOMENA;

EID: 84955172501     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2015.01.010     Document Type: Review

References (195)

1. Abrishami M., Zarei-Ghanavati S., Soroush D., Rouhbakhsh M., Jaafari M.R., Malaekeh-Nikouei B. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (Avastin) for intravitreal administration. Retin J Retin Vitreous Dis 2011, 31:205. (vol 29, pg 699, 2009).
2. Aggarwal R.S. What's fueling the biotech engine - 2012 to 2013. Nat Biotechnol 2014, 32:32-39.
3. Alghadyan A.A., Peyman G.A., Khoobehi B., Milner S., Liu K.R. Liposome-bound cyclosporine - aqueous and vitreous level after sub-conjunctival injection. Int Ophthalmol 1988, 12:101-104.
4. Alghadyan A.A., Peyman G.A., Khoobehi B., Milner S., Liu K.R. Liposome-bound cyclosporine - clearance after intravitreal injection. Int Ophthalmol 1988, 12:109-112.
5. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013, 65:36-48.
6. Almeida A.J., Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007, 59:478-490.
7. Al-Qadi S., Grenha A., Carrion-Recio D., Seijo B., Remunan-Lopez C. Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations. J Control Release 2012, 157:383-390.
8. Amsden B.G., Goosen M.F.A. Transdermal delivery of peptide and protein drugs: an overview. AIChE J 1995, 41:1972-1997.
9. Andrade F., Videira M., Ferreira D., Sarmento B. Nanocarriers for pulmonary of peptides and therapeutic proteins. Nanomedicine 2011, 6:123-141.
10. Antosova Z., Mackova M., Kral V., Macek T. Therapeutic application of peptides and proteins: parenteral forever?. Trends Biotechnol 2009, 27:628-635.
11. Arias J. Liposomes in drug delivery: a patent review (2007-present). Expert Opin Ther Pat 2013, 23:1399-1414.
12. Aufenvenne K., Larcher F., Hausser I., Duarte B., Oji V., Nikolenko H., et al. Topical enzyme-replacement therapy restores transglutaminase 1 activity and corrects architecture of transglutaminase-1-deficient skin grafts. Am J Hum Genet 2013, 93:620-630.
13. Azarmi S., Roa W.H., Lobenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev 2008, 60:863-875.
14. Baca-Estrada M.E., Foldvari M., Babiuk S.L., Babiuk L.A. Vaccine delivery: lipid-based delivery systems. J Biotechnol 2000, 83:91-104.
15. Baleeiro R.B., Wiesmuller K.-H., Reiter Y., Baude B., Dahne L., Patzelt A., et al. Topical vaccination with functionalized particles targeting dendritic cells. J Invest Dermatol 2013, 133:1933-1941.
16. Banchereau J.S., Ralph M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
17. Bao G., Mitragotri S., Tong S. Multifunctional nanoparticles for drug delivery and molecular imaging. Annu Rev Biomed Eng 2013, 15:253-282.
18. Bechtold-Peters K. Pulmonary drug delivery - special formulation aspects for biotech compounds. Pulmonary drug delivery 2007, 196-221. Editio Cantor Verlag, Aulendorf. K. Bechtold-Peters, H. Luessen (Eds.).
19. Beck-Broichsitter M., Merkel O.M., Kissel T. Controlled pulmonary drug and gene delivery using polymeric nano-carriers. J Control Release 2012, 161:214-224.
20. Berard F., Marty J., Nicolas J. Allergen penetration through the skin. Eur J Dermatol 2003, 13:324-330.
21. Bi R., Shao W., Wang Q., Zhang N. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J Drug Target 2008, 16:639-648.
22. Bivas-Benita M., Lin M.Y., Bal S.M., van Meijgaarden K.E., Franken K.L., Friggen A.H., et al. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine 2009, 27:4010-4017.
23. Blank F., Strumbles P., von Garnier C. Opportunities and challenges of the pulmonary route for vaccination. Expert Opin Drug Deliv 2011, 8:547-563.
24. Bochot A., Fattal E. Liposomes for intravitreal drug delivery: a state of the art. J Control Release 2012, 161:628-634.
25. Bosquillon C., Preat V., Vanbever R. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J Control Release 2004, 96:233-244.
26. Briscone P., Caniggai I., Graves A., Benson B., Huang L., Tanswell A., et al. Delivery of superoxide dismutase to pulmonary epithelium via pH sensitive liposomes. Am J Physiol 1995, 268:L374-L380.
27. Brown M.B., Martin G.P., Jones S.A., Akomeah F.K. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv 2006, 13:175-187.
28. Brown M., Traynor M., Martin G., Akomeah F. Transdermal drug delivery systems: skin perturbation devices. Drug delivery systems 2008, 119-139. Humana Press. K. Jain (Ed.).
29. Brueck A., Abu-Dahab R., Borchard G., Schaefer U., Lehr C. Lectin-functionalized liposomes for pulmonary drug delivery: interaction with human alveolar epithelial cells. J Drug Target 2001, 9:241-251.
30. Calvo P., Sanchez A., Martinez J., Lopez M.I., Calonge M., Pastor J.C., et al. Polyester nanocapsules as new topical ocular delivery systems for cyclosporine A. Pharm Res. 1996, 13(2):311-315.
31. Camelo S., Lajavardi L., Bochot A., Goldenberg B., Naud M.C., Fattal E., et al. Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats. Mol Vis 2007, 13:2263-2274.
32. Chang S.-L., Hofmann G.A., Zhang L., Deftos L.J., Banga A.K. Transdermal iontophoretic delivery of salmon calcitonin. Int J Pharm 2000, 200:107-113.
33. Chen L., Zhu J., Li Y., Lu J., Gao L., Xu H., et al. Enhanced nasal mucosal delivery and immunogenicity of anti-caries DNA vaccine through incorporation of anionic liposomes in chitosan/DNA complexes. PLoS One 2013, 8:e71953.
34. Chono S., Fukuchi R., Seki T., Morimoto K. Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. J Control Release 2009, 137:104-109.
35. Chow S., Di Girolamo N. Vitronectin: a migration and wound healing factor for human corneal epithelial cells. Invest Ophthalmol Vis Sci 2014, 55:6590-6600.
36. Cipolla D., Shekunov B., Blanchard J., Hickey A. Lipid-based carriers for pulmonary products: preclinical development and case studies in humans. Adv Drug Deliv Rev 2014, 75C:53-80.
37. Claus S., Weiler C., Schiewe J., Friess W. Optimization of the fine particle fraction of a lyophilized lysozyme formulation for dry powder inhalation. Pharm Res 2013, 30:1698-1713.
38. Codrons V., Vanderbist F., Ucakar B., Preat V., Vanbever R. Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J Pharm Sci 2004, 93:1241-1252.
39. Crommelin D.J.A., Storm G., Verrijk R., de Leede L., Jiskoot W., Hennink W.E. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm 2003, 266:3-16.
40. Cromwell M.M., Hilario E., Jacobson F. Protein aggregation and bioprocessing. AAPS J 2006, 8:E572-E579.
41. Cryan S.A. Carrier-based strategies for targeting protein and peptide drugs to the lung. AAPS J 2005, 7:E20-E41.
42. Cuggino J.C., Alvarez C.I., Strumia M.C., Welker P., Licha K., Steinhilber D., et al. Thermosensitive nanogels based on dendritic polyglycerol and N-isopropylacrylamide for biomedical applications. Soft Matter 2011, 7:11259-11266.
43. d'Angelo I., Conte C., La Rotonda M.I., Miro A., Quaglia F., Ungaro F. Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies. Adv Drug Deliv Rev 2014, 75C:92-111.
44. Dawson M., Krauland E., Wirtz D., Hanes J. Transport of polymeric nanoparticle gene carriers in gastric mucus. Biotechnol Prog 2004, 20:851-857.
45. Degim T., Celebi N. Controlled delivery of peptides and proteins. Curr Pharm Des 2007, 13:99-117.
46. Del Amo E.M., Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today 2008, 13:135-143.
47. Deshpande P.P., Biswas S., Torchilin V. Current trends in the use of liposomes for tumor targeting. Nanomedicine 2013, 8:1509-1528.
48. Di Tommaso C., Torriglia A., Furrer P., Behar-Cohen F., Gurny R., Moller M. Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers. Int J Pharm 2011, 416:515-524.
49. Ding S.L. Recent developments in ophthalmic drug delivery. Pharm Sci Technol Today 1998, 1:328-335.
50. Ducreux J., Vanbever R. Crucial biopharmaceutical issues facing macromolecular candidates for inhalation: the role of macrophages in pulmonary protein clearance. Respir Drug Deliv Eur 2007, 31-42.
51. Ebrahim S., Peyman G.A., Lee P.J. Applications of liposomes in ophthalmology. Surv Ophthalmol 2005, 50:167-182.
52. El Sanharawi M., Kowalczuk L., Touchard E., Omri S., de Kozak Y., Behar-Cohen F. Protein delivery for retinal diseases: from basic considerations to clinical applications. Prog Retin Eye Res 2010, 29:443-465.
53. Ferrari S., Kitson C., Farley R., Steel R., Marriott C., Parkins D., et al. Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium. Gene Ther 2001, 8:1380-1386.
54. Fleige E., Quadir M.A., Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv Drug Deliv Rev 2012, 64:866-884.
55. Foldvari M. Biphasic vesicles: a novel topical drug delivery system. J Biomed Nanotechnol 2010, 6:543-557.
56. Foldvari M., Badea I., Wettig S., Baboolal D., Kumar P., Creagh A.L., et al. Topical delivery of interferon alpha by biphasic vesicles: evidence for a novel nanopathway across the stratum corneum. Mol Pharm 2010, 7:751-762.
57. Fröhlich E., Roblegg E. Mucus as barrier for drug delivery by nanoparticles. J Nanosci Nanotechnol 2014, 14:126-136.
58. Frokjaer S., Otzen D.E. Protein drug stability: a formulation challenge. Nat Rev Drug Discov 2005, 4:298-306.
59. Garcia-Contreras L., Wong Y.L., Muttil P., Padilla D., SadoffJ., Derousse J., et al. Immunization by a bacterial aerosol. Proc Natl Acad Sci U S A 2008, 105:4656-4660.
60. Gariano R.F., Gardner T.W. Retinal angiogenesis in development and disease. Nature 2005, 438:960-966.
61. Geroski D.H., Edelhauser H.F. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci 2000, 41:961-964.
62. Goebel A.S., Schmaus G., Neubert R.H., Wohlrab J. Dermal peptide delivery using enhancer molecules and colloidal carrier systems - part I: carnosine. Skin Pharmacol Physiol 2012, 25:281-287.
63. GraffC.L., Pollack G.M. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci 2005, 94:1187-1195.
64. Grenha A., Remunan-Lopez C., Carvalho E.L., Seijo B. Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur J Pharm Biopharm 2008, 69:83-93.
65. Gumbleton M., Morris C., Francombe D., Sakagami M. Drug transport processes of the air-blood barrier. Pulmonary drug delivery 2007, 332-353. Editio Cantor Verlag, Aulendorf. K. Bechtold-Peters, H. Luessen (Eds.).
66. Hadebe S.I., Ngubane P.S., Serumula M.R., Musabayane C.T. Transdermal delivery of insulin by amidated pectin hydrogel matrix patch in streptozotocin-induced diabetic rats: effects on some selected metabolic parameters. PLoS One 2014, 9:e101461.
67. Hansen S., Lehr C.M. Transfollicular delivery takes root: the future for vaccine design?. Expert Rev Vaccines 2014, 13:5-7.
68. Hermans K., Van Den Plas D., Schreurs E., Weyenberg W., Ludwig A. Cytotoxicity and anti-inflammatory activity of cyclosporine A loaded PLGA nanoparticles for ocular use. Pharmazie 2014, 69:32-37.
69. Hertel S. Protein stability in pulmonary drug delivery via nebulization 2014, LMU, Munich.
70. Holland S., Morck D., Schultz C. Treatment of corneal defects with delayed re-epithelization with a medical device/drug delivery system for epidermal growth factor. Clin Experiment Ophthalmol 2012, 40:662-668.
71. Huang Y.Y., Wang C.H. Pulmonary delivery of insulin by liposomal carriers. J Control Release 2006, 113:9-14.
72. Hughes P.M., Olejnik O., Chang-Lin J.E., Wilson C.G. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev 2005, 57:2010-2032.
73. Illum L. Nasal drug delivery - possibilities, problems and solutions. J Control Release 2003, 87:187-198.
74. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000, 21:2475-2490.
75. Jain A.K., Chalasani K.B., Khar R.K., Ahmed F.J., Diwan P.V. Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery. J Drug Target 2007, 15:417-427.
76. Jain A., Jain A., Gulbake A., Shilpi S., Hurkat P., Jain S.K. Peptide and protein delivery using new drug delivery systems 2013, 30:293-329.
77. Jameel F., Hershenson S. Formulation and process development strategies for manufacturing biopharmaceuticals 2010, Wiley, New Jersey.
78. Jepps O.G., Dancik Y., Anissimov Y.G., Roberts M.S. Modeling the human skin barrier - towards a better understanding of dermal absorption. Adv Drug Deliv Rev 2013, 65:152-168.
79. Jiskoot W., Randolph T.W., Volkin D.B., Middaugh C.R., Schoneich C., Winter G., et al. Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci 2012, 101:946-954.
80. Juberias J.R., Calonge M., Gomez S., Lopez M.I., Calvo P., Herreras J.M., et al. Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat. Curr Eye Res 1998, 17:39-46.
81. Juliano R. Challenges to macromolecular drug delivery. Biochem Soc Trans 2007, 35:41-43.
82. Kaipel M., Wagner A., Wassermann E., Vorauer-Uhl K., Kellner R., Redl H., et al. Increased biological half-life of aerosolized liposomal recombinant human Cu/Zn superoxide dismutase in pigs. J Aerosol Med Pulm Drug Deliv 2008, 21:281-290.
83. Kalluri H., Banga A. Transdermal delivery of proteins. AAPS PharmSciTech 2011, 12:431-440.
84. Kammona O., Kiparissides C. Recent advances in nanocarrier-based mucosal delivery of biomolecules. J Control Release 2012, 161:781-794.
85. Karagiannis E.D., Popel A.S. A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Natl Acad Sci U S A 2008, 105:13775-13780.
86. Kawabata A., Baoum A., Ohta N., Jacquez S., Seo G.M., Berkland C., et al. Intratracheal administration of a nanoparticle-based therapy with the angiotensin II type 2 receptor gene attenuates lung cancer growth. Cancer Res 2012, 72:2057-2067.
87. Kawashima Y., Yamamoto H., Takeeuchi H., Fujioka S., Hino T. Pulmonary delivery of insulin with nebulized dl-lactide/glycoside copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release 1999, 62:279-287.
88. Khanna C., Anderson P., Hasz D., Katsanis E., Neville M., Klausner J. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 1997, 79:1409-1421.
89. King M.J., Badea I., Solomon J., Kumar P., Gaspar K.J., Foldvari M. Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technol Ther 2002, 4:479-488.
90. King M.J., Michel D., Foldvari M. Evidence for lymphatic transport of insulin by topically applied biphasic vesicles. J Pharm Pharmacol 2003, 55:1339-1344.
91. King M., Kumar P., Michel D., Batta R., Foldvari M. In vivo sustained dermal delivery and pharmacokinetics of interferon alpha in biphasic vesicles after topical application. Eur J Pharm Biopharm 2013, 84:532-539.
92. Kleemann E., Neu M., Jekel N., Fink L., Schmehl T., Gessler T., et al. Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J Control Release 2005, 109:299-316.
93. KohlhäuflM. Understanding clinical aerosol therapy: physiological aspects of the respiratory system and current inhalation therapy in chronic obstructive pulmonary disease and asthma. Pulmonary drug delivery 2007, 16-45. Editio Cantor Verlag, Aulendorf. K. Bechtold-Peters, H. Luessen (Eds.).
94. Koskimaki J.E., Rosca E.V., Rivera C.G., Lee E., Chen W., Pandey N.B., et al. Serpin-derived peptides are antiangiogenic and suppress breast tumor xenograft growth. Transl Oncol 2012, 5:92-97.
95. Koussoroplis S.-J., Vanbever R. Peptides and proteins: pulmonary absorption. Encycl Pharm Sci Technol 2013, 4:2607-2618.
96. Koyamatsu Y., Hirano T., Kakizawa Y., Okano F., Takarada T., Maeda M. pH-responsive release of proteins from biocompatible and biodegradable reverse polymer micelles. J Control Release 2014, 173:89-95.
97. Kubek M.J., Domb A.J., Veronesi M.C. Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles. Neurotherapeutics 2009, 6:359-371.
98. Lai S.K., Wang Y.Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009, 61:158-171.
99. Lajavardi L., Camelo S., Agnely F., Luo W., Goldenberg B., Naud M.C., et al. New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis. J Control Release 2009, 139:22-30.
100. Lallemand F., Felt-Baeyens O., Besseghir K., Behar-Cohen F., Gurny R. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm 2003, 56:307-318.
101. Lange C., Hancock R., Samuel J., Finlay W. In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide. J Pharm Sci 2001, 90:1647-1657.
102. Law S.L., Huang K.J., Chiang C.H. Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption. J Control Release 2000, 63:135-140.
103. Law S.L., Huang K.J., Chou V.H., Cherng J.Y. Enhancement of nasal absorption of calcitonin loaded in liposomes. J Liposome Res 2001, 11:165-174.
104. Lee Y., Ishii T., Cabral H., Kim H.J., Seo J.H., Nishiyama N., et al. Charge-conversional polyionic complex micelles-efficient nanocarriers for protein delivery into cytoplasm. Angew Chem Int Ed Engl 2009, 48:5309-5312.
105. Lee C., Choi J.S., Kim I., Oh K.T., Lee E.S., Park E.S., et al. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes. Int J Nanomedicine 2013, 8:2975-2983.
106. Li H., Tran V.V., Hu Y., Mark Saltzman W., Barnstable C.J., Tombran-Tink J. A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. Exp Eye Res 2006, 83:824-833.
107. Li N., Peng L.H., Chen X., Nakagawa S., Gao J.Q. Effective transcutaneous immunization by antigen-loaded flexible liposome in vivo. Int J Nanomedicine 2011, 6:3241-3250.
108. Ling M.-H., Chen M.-C. Dissolving polymer microneedle patches for rapid and efficient transdermal delivery of insulin to diabetic rats. Acta Biomater 2013, 9:8952-8961.
109. Liu J., Gong T., Fu H., Wang C., Wang X., Chen Q., et al. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm 2008, 356:333-344.
110. Liu S., Jones L., Gu F.X. Development of mucoadhesive drug delivery system using phenylboronic acid functionalized poly(d, l-lactide)-b-dextran nanoparticles. Macromol Biosci 2012, 12:1622-1626.
111. Loira-Pastoriza C., TodoroffJ., Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev 2014, 75:81-91.
112. Lopez-Vidriero M., Reid L. Bronchial mucus in health and disease. Br Med Bull 1978, 34:63-74.
113. Lu D., Hickey A. Liposomal dry powders as aerosols for pulmonary delivery of proteins. AAPS PharmSciTech 2005, 6:E641-E647.
114. Lu Y., Sun W., Gu Z. Stimuli-responsive nanomaterials for therapeutic protein delivery. J Control Release 2014, 194:1-19.
115. Luppi B., Bigucci F., Cerchiara T., Zecchi V. Chitosan-based hydrogels for nasal drug delivery: from inserts to nanoparticles. Expert Opin Drug Deliv 2010, 7:811-828.
116. Maa Y., Prestrekski S. Biopharmaceutical powders: particle formation and formulation considerations. Curr Pharm Biotechnol 2000, 1:283-302.
117. Mahler H.-C., Friess W., Grauschopf U., Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci 2009, 98:2909-2934.
118. Mahler H.-C., Borchard G., Luessen H. Protein pharmaceuticals 2010, Editio Cantor Verlag, Aulendorf.
119. Mainardes R.M., Urban M.C., Cinto P.O., Chaud M.V., Evangelista R.C., Gremiao M.P. Liposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery. Curr Drug Deliv 2006, 3:275-285.
120. Malerba F., Paoletti F., Capsoni S., Cattaneo A. Intranasal delivery of therapeutic proteins for neurological diseases. Expert Opin Drug Deliv 2011, 8:1277-1296.
121. Manosroi J., Lohcharoenkal W., Götz F., Werner R.G., Manosroi W., Manosroi A. Transdermal absorption and stability enhancement of salmon calcitonin by Tat peptide. Drug Dev Ind Pharm 2013, 39:520-525.
122. Marianecci C., Di Marzio L., Rinaldi F., Carafa M., Alhaique F. Pulmonary delivery innovative approaches and perspectives. J Biomater Nanobiotechnol 2011, 2:567-575.
123. Marques A., Turner A., De Mello R. Personalizing medicine for metastatic colorectal cancer: current developments. World J Gastroenterol 2014, 20:10425-10431.
124. Mattheolabakis G., Lagoumintzis G., Panagi Z., Papadimitriou E., Partidos C.D., Avgoustakis K. Transcutaneous delivery of a nanoencapsulated antigen: induction of immune responses. Int J Pharm 2010, 385:187-193.
125. McGrath J.A., Eady R.A.J., Pope F.M. Anatomy and organization of human skin. Rook's textbook of dermatology 2008, 45-128. Blackwell Publishing, Inc.
126. Menon G.K., Cleary G.W., Lane M.E. The structure and function of the stratum corneum. Int J Pharm 2012, 435:3-9.
127. Menon J.U., Ravikumar P., Pise A., Gyawali D., Hsia C.C., Nguyen K.T. Polymeric nanoparticles for pulmonary protein and DNA delivery. Acta Biomater 2014, 10:2643-2652.
128. Migliore M.M., Vyas T.K., Campbell R.B., Amiji M.M., Waszczak B.L. Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J Pharm Sci 2010, 99:1745-1761.
129. Mitragotri S., Burke P., Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov 2014, 13:655-672.
130. Mittal A., Raber A.S., Schaefer U.F., Weissmann S., Ebensen T., Schulze K., et al. Non-invasive delivery of nanoparticles to hair follicles: a perspective for transcutaneous immunization. Vaccine 2013, 31:3442-3451.
131. Mittal A., Schulze K., Ebensen T., Weißmann S., Hansen S., Lehr C.M., et al. Efficient nanoparticle-mediated needle-free transcutaneous vaccination via hair follicles requires adjuvantation. Nanomed Nanotechnol 2014, 11:147-154.
132. Mohamud R., Xiang S.D., Selomulya C., Rolland J.M., O'Hehir R.E., Hardy C.L., et al. The effects of engineered nanoparticles on pulmonary immune homeostasis. Drug Metab Rev 2014, 46:176-190.
133. Mondon K., Zeisser-Labouebe M., Gurny R., Moller M. Novel cyclosporin A formulations using MPEG-hexyl-substituted polylactide micelles: a suitability study. Eur J Pharm Biopharm 2011, 77:56-65.
134. Murata M., Nakano K., Tahara K., Tozuka Y., Takeuchi H. Pulmonary delivery of elcatonin using surface-modified liposomes to improve systemic absorption: polyvinyl alcohol with a hydrophobic anchor and chitosan oligosaccharide as effective surface modifiers. Eur J Pharm Biopharm 2012, 80:340-346.
135. Murata M., Yonamine T., Tanaka S., Tahara K., Tozuka Y., Takeuchi H. Surface modification of liposomes using polymer-wheat germ agglutinin conjugates to improve the absorption of peptide drugs by pulmonary administration. J Pharm Sci 2013, 102:1281-1289.
136. Nagarwal R.C., Kant S., Singh P.N., Maiti P., Pandit J.K. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release 2009, 136:2-13.
137. Natarajan V.T., Ganju P., Ramkumar A., Grover R., Gokhale R.S. Multifaceted pathways protect human skin from UV radiation. Nat Chem Biol 2014, 10:542-551.
138. Nyambura B.K., Kellaway I.W., Taylor K.M. The processing of nanoparticles containing protein for suspension in hydrofluoroalkane propellants. Int J Pharm 2009, 372:140-146.
139. Paliwal S.R., Paliwal R., Vyas S.P. pH-sensitive Liposomes in Drug Delivery. Smart Materials for Drug Delivery: Volume 1 2013, 80-93. Royal Society of Chemistry. C.C. Alvarez-Lorenzo, A (Eds.).
140. Pasparakis M., Haase I., Nestle F.O. Mechanisms regulating skin immunity and inflammation. Nat Rev Immunol 2014, 14:289-301.
141. Patton J.S., Fishburn C.S., Weers J.G. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004, 1:338-344.
142. Paudel K.S., Milewski M., Swadley C.L., Brogden N.K., Ghosh P., Stinchcomb A.L. Challenges and opportunities in dermal/transdermal delivery. Ther Deliv 2010, 1:109-131.
143. Pawar D., Mangal S., Goswami R., Jaganathan K.S. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity. Eur J Pharm Biopharm 2013, 85:550-559.
144. Piroyan A., Koshkaryev A., Riehle R., Torchilin V. Polymer-modified liposomes: from long-circulating to multifunctional. Liposomes, lipid bilayers and model membranes 2014, 317-339. G. Pabst (Ed.).
145. Prausnitz M.R., Langer R. Transdermal drug delivery. Nat Biotechnol 2008, 26:1261-1268.
146. Raber A.S., Mittal A., Schäfer J., Bakowsky U., Reichrath J., Vogt T., et al. Quantification of nanoparticle uptake into hair follicles in pig ear and human forearm. J Control Release 2014, 179:25-32.
147. Rowe-Rendleman C.L., Durazo S.A., Kompella U.B., Rittenhouse K.D., Di Polo A., Weiner A.L., et al. Drug and gene delivery to the back of the eye: from bench to bedside. Invest Ophthalmol Vis Sci 2014, 55:2714-2730.
148. Rubin B.K., Williams R.W. Emerging aerosol drug delivery strategies: from bench to clinic. Adv Drug Deliv Rev 2014, 75C:141-148.
149. Ruge C., Schaefer U.F., Herrmann J., Kirch J., Canadas O., Echaide M., et al. The interplay of lung surfactant proteins and lipids assimilates the macrophage clearance of nanoparticles. PLoS One 2012, 7:1-10.
150. Rytting E., Nguyen J., Wang X., Kissel T. Biodegradable polymeric nanocarries for pulmonary drug delivery. Expert Opin Drug Deliv 2008, 5:629-639.
151. Sakai T., Kuno N., Takamatsu F., Kimura E., Kohno H., Okano K., et al. Prolonged protective effect of basic fibroblast growth factor-impregnated nanoparticles in royal college of surgeons rats. Invest Ophthalmol Vis Sci 2007, 48:3381-3387.
152. Sanders N., De Smedt S., Van Rompaey E., Simoens P., De Baets F., Demeester J. Cystic fibrosis sputum: a barrier to the transport of nanospheres. Am J Respir Crit Care Med 2000, 162:1905-1911.
153. Sato A.K., Viswanathan M., Kent R.B., Wood C.R. Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 2006, 17:638-642.
154. Schleh C., Rothen-Rutishauser B., Kreyling W.G. The influence of pulmonary surfactant on nanoparticulate drug delivery systems. Eur J Pharm Biopharm 2011, 77:350-352.
155. Scholl S., Beuzeboc P., Pouillart P. Targeting HER2 in other tumor types. Ann Oncol 2001, 12:S81-S87.
156. Schwartz S.G., Scott I.U., Flynn H.W., Stewart M.W. Drug delivery techniques for treating age-related macular degeneration. Expert Opin Drug Deliv 2014, 11:61-68.
157. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat Rev Cancer 2012, 12:278-287.
158. Shahiwala A., Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder: a technical note. AAPS PharmSciTech 2005, 6:E482-E486.
159. Sharma S., Benson H.A., Mukkur T.K., Rigby P., Chen Y. Preliminary studies on the development of IgA-loaded chitosan-dextran sulphate nanoparticles as a potential nasal delivery system for protein antigens. J Microencapsul 2013, 30:283-294.
160. Shmueli R.B., Ohnaka M., Miki A., Pandey N.B., Lima e Silva R., Koskimaki J.E., et al. Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide. Biomaterials 2013, 34:7544-7551.
161. Sintov A.C., Wormser U. Topical iodine facilitates transdermal delivery of insulin. J Control Release 2007, 118:185-188.
162. Smith F.J.D., Irvine A.D., Terron-Kwiatkowski A., Sandilands A., Campbell L.E., Zhao Y., et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 2006, 38:337-342.
163. Soussan E., Cassel S., Blanzat M., Rico-Lattes I. Drug delivery by soft matter: matrix and vesicular carriers. Angew Chem 2009, 48:274-288.
164. Stark B., Debbage P., Andreae F., Mosgoeller W., Prassl R. Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery. Biochim Biophys Acta 2007, 1768:705-714.
165. Stout T.E., McFarland T., Mitchell J.C., Appukuttan B., Timothy Stout J. Recombinant filaggrin is internalized and processed to correct filaggrin deficiency. J Invest Dermatol 2014, 134:423-429.
166. Tamber H., Johansen P., Merkle H.P., Gander B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Deliv Rev 2005, 57:357-376.
167. Tan M.L., Choong P.F.M., Dass C.R. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides 2010, 31:184-193.
168. Taratula O., Garbuzenko O.B., Chen A.M., Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target 2011, 19:900-914.
169. Tas C., Mansoor S., Kalluri H., Zarnitsyn V.G., Choi S.-O., Banga A.K., et al. Delivery of salmon calcitonin using a microneedle patch. Int J Pharm 2012, 423:257-263.
170. Teijeiro-Osorio D., Remunan-Lopez C., Alonso M.J. New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules. Biomacromolecules 2009, 10:243-249.
171. Ten R., Anderson P., Zein N., Temesgen Z., Clawson M., Weiss W. Interleukin-2 liposomes for primary immune deficiency using the aerosol route. Int Immunopharmacol 2002, 2:333-344.
172. Upadhyay D., Scalia S., Vogel R., Wheate N., Salama R.O., Young P.M., et al. Magnetised thermo responsive lipid vehicles for targeted and controlled lung drug delivery. Pharm Res 2012, 29:2456-2467.
173. Uzor P., Mbah C., Omeje E. Perspectives on transdermal drug delivery. J Chem Pharm Res 2011, 3:680-700.
174. Van der Walle C. Peptide and protein delivery. An overview of the field of peptide and protein delivery 2011, Academic Press. V.D.W. CO, O (Eds.).
175. Varshochian R., Jeddi-Tehrani M., Mahmoudi A.R., Khoshayand M.R., Atyabi F., Sabzevari A., et al. The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments. Eur J Pharm Sci 2013, 50:341-352.
176. Vyas T.K., Shahiwala A., Marathe S., Misra A. Intranasal drug delivery for brain targeting. Curr Drug Deliv 2005, 2:165-175.
177. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 2005, 289:1-30.
178. Wang H.W., Jiang P.L., Lin S.F., Lin H.J., Ou K.L., Deng W.P., et al. Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization. Acta Biomater 2013, 9:5681-5688.
179. Wang Y., Zhang X., Cheng C., Li C. Mucoadhesive and enzymatic inhibitory nanoparticles for transnasal insulin delivery. Nanomedicine (Lond) 2014, 9:451-464.
180. Wang W., Sreekumar P.G., Valluripalli V., Shi P., Wang J., Lin Y.A., et al. Protein polymer nanoparticles engineered as chaperones protect against apoptosis in human retinal pigment epithelial cells. J Control Release 2014, 191:4-14.
181. Wertz P.W. Current understanding of skin biology pertinent to skin penetration: skin biochemistry. Skin Pharmacol Physiol 2013, 26:217-226.
182. Yadav S.C., Kumari A., Yadav R. Development of peptide and protein nanotherapeutics by nanoencapsulation and nanobioconjugation. Peptides 2011, 32:173-187.
183. Yamamoto A., Umemori S., Muranishi S. Absorption enhancement of intrapulmonary administered insulin by various absorption enhancers and protease inhibitors in rats. J Pharm Pharmacol 1994, 46:14-18.
184. Yamamoto H., Kuno Y., Sugimoto S., Takeuchi H., Kawashima Y. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release 2005, 102:373-381.
185. Yamamoto H., Hoshina W., Kurashima, Takeuchi, Kawashima, Yokoyama, et al. Engineering of poly(dl-lactic-co-glycolic acid) nanocomposite particles for dry powder inhalation. Adv Powder Technol 2007, 18:215-228.
186. Yandrapu S.K., Upadhyay A.K., Petrash J.M., Kompella U.B. Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab. Mol Pharm 2013, 10:4676-4686.
187. Yang W., Peters J.I., Williams R.O. Inhaled nanoparticles - a current review. Int J Pharm 2008, 356:239-247.
188. Yang M., Yamamoto H., Kurashima H., Takeuchi H., Yokoyama T., Tsujimoto H., et al. Design and evaluation of poly(dl-lactic-co-glycolic acid) nanocomposite particles containing salmon calcitonin for inhalation. Eur J Pharm Sci 2012, 46:374-380.
189. Yang L., Luo J., Shi S., Zhang Q., Sun X., Zhang Z., et al. Development of a pulmonary peptide delivery system using porous nanoparticle-aggregate particles for systemic application. Int J Pharm 2013, 451:104-111.
190. Zhang Q., Shen Z., Nagai T. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int J Pharm 2001, 218:75-80.
191. Zhang L., Gu F.X., Chan J.M., Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2007, 83:761-769.
192. Zhang K., Zhang L., Weinreb R.N. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov 2012, 11:541-559.
193. Zhang C., Chen J., Feng C., Shao X., Liu Q., Zhang Q., et al. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease. Int J Pharm 2014, 461:192-202.
194. Zhao Y.Z., Li X., Lu C.T., Xu Y.Y., Lv H.F., Dai D.D., et al. Experiment on the feasibility of using modified gelatin nanoparticles as insulin pulmonary administration system for diabetes therapy. Acta Diabetol 2012, 49:315-325.
195. Zheng C., Guo Q., Wu Z., Sun L., Zhang Z., Li C., et al. Amphiphilic glycopolymer nanoparticles as vehicles for nasal delivery of peptides and proteins. Eur J Pharm Sci 2013, 49:474-482.